Genome Editing Market Analysis Report By Technology, By Delivery Method, By Application, By Mode, By End-use, By Region And Segment Forecasts From 2021 To 2028

Synopsis

The global genome editing market was prized by USD 3.7 billion in 2020. It is estimated to witness 22.9% CAGR from 2021 to 2028.

Drivers

Rising execution of CRISPR genome editing tools, together with increasing demand for the synthetic gene in various biotechnology areas has mainly steered the expansion of the market for genome editing, during the previous only some years. Despite this, incessant scientific progressions in gene-editing tools are the most important adding factor for revenue creation, within this market.

Due to the increasing function of genome editing tools, the market for genome editing is observing strong rivalry between the companies. There has been a better concentration on the very much adjustable CRISPR tools.

Technology Insight

The CRISPR/Cas9 section held the major, 40.2% revenue share and led the market for genome editing, in 2020. This procedure has transformed the genome manipulation space by its technological advantages. These returns consist of regulation, targeted gene disruption, and recovery in a guide RNA-specific manner. These advantages have stepped up the acceptance of CRISPR/Cas9 technology, through extensive functions.

The restrictions of CRISPR technology have augmented use of the TALEN method in several hard-to-edit genomic regions. Consistent with a report published in January 2021, TALEN is observed to be an additionally appropriate means for the compact DNA research. These reviews would augment the implementation of the TALEN method in research background, during the near future.

Delivery Method Insight

The ex-vivo delivery method sector held the biggest 57.2% revenue share and led the market for genome editing, in 2020. This can be credited to the returns presented by this method type for example easiness of management in DNA modification.

The increasing development of clinical trial, which organizes genome editing tools, has stimulated expansion of the ex-vivo delivery sector by means of the amplified use of this delivery method.

Conversely, the in-vivo gene delivery method formed lesser revenue creation owing to the challenges that happen throughout the procedure, for instance off-target effects. But, concentrated efforts are taken to conquer the challenges, via increasing clinical trials paying attention on simple target tissues, using in-vivo delivery.

Application Insight

By way of the cell line engineering at the front position, holding biggest 58.8% revenue share of the market for genome editing, in 2020, the progress in gene editing method have transformed the genetic engineering section. This can be credited to the speedily increasing area of gene as well as stem cell treatment.

The clinical application held the large revenue share and led the market for genome editing in 2020. In addition, genetic engineering, genome editing expertise has greater prospective enlargement in clinical functions, like treatment and diagnostics improvement.

Effect of Covid-19

The advancement of CRISPR sourced new investigative tools, to lessen the unfavorable effect of the Covid-19 pandemic is, moreover, inspiring the market for genome editing. For example, a group of researchers from the Nan yang Technological University build up an analytic examination – VaN Guard (Variant Nucleotide Guard) on the basis of CRISPR tools, in March 2021. This test is capable to discover mutated SARS-CoV-2 varieties, by this means raising the implementation of CRISPR genome editing tools in the diagnostics field.

Mode Insight

In 2020, the contract-based genome editing sector held the 51.9% revenue share and led the market for genome editing. The elevated prices of connected infrastructure together with rising partnerships amid market units have caused a considerable share of the market of contract services, within the international market.

End Use Insight

The biotechnology and pharmaceutical companies division held the major 48.4% revenue share andled the market for genome editing, in 2020.The existence of an increasing amount of research actions, intended for the occurrence of new therapeutic, is the most important issue encouraging revenue creation by the division.

Besides, international pharmaceutical companies are working in partnership with rising companies, to build on fresh technologies. Then again, government academic and research institutes are expected to observe strong enlargement during the nearby prospect, because of the rising use of gene-editing technologies in university stage undertakings. Operational engagement of research organizations additionally increases the development of the sector.

Regional Insight

In 2020, North America held the main, 38.4% revenue share and led the global market for genome editing. The existence of robust commercial plus research basis, which is used for the development of sophisticated treatment, together with a greater amount of clinical trials being performed, in favor of stem cell and gene treatments in the region, has mainly played a role in the domination of the market, within the region.

Besides, the rising amount of the patents given to the U.S. sourced major companies has, furthermore, stepped up the making use of these tools in the nation, causing the major enlargement of the market. Such as, in recent times, Merck KGaA declared that two patents of the company have been accepted in the U.S. meant for the CRISPR gene-editing technologies.

In contrast, the market in Asia Pacific is expected to observe the highest development percentage, during the forecast period. China publicized its ten most important progresses of the farming division, in November 2020. Out of it one was gene-editing technology, therefore signifying the greater market infiltration of this place, within the nation.

Companies

Majority of the companies are taking on licensing contract with the developers of technology to increase their existence in the market.

Some of the companies for genome editing market are:

    • Lonza
    • New England Bio labs
    • Egenesis Inc.
    • Horizon Discovery Group plc
    • AstraZeneca
    • Caribou Biosciences, Inc.
    • CRISPR Therapeutics
    • Editas Medicine
    • Cibus, Recombine tics, Inc.
    • Thermo Fisher Scientific, Inc.
    • Ori Gene Technologies, Inc.
    • GenScript
    • Integrated DNA Technologies, Inc.
    • Takara Bio USA
    • Cellectis S.A.
    • Intellia Therapeutics, Inc.
    • Precision Biosciences
    • Sangamo
    • Merck KGaA

Report Scope 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Million Insights has segmented the global genome editing market report on the basis of technology, delivery method, application, mode, end-use, and region:

• Technology Outlook (Revenue, USD Million, 2017 - 2028)
    • Meganucleases
    • (CRISPR)/Cas9
    • TALENs/MegaTALs
    • ZFN
    • Others

• Delivery Method Outlook (Revenue, USD Million, 2017 - 2028)
    • Ex-vivo
    • In-vivo

• Mode Outlook (Revenue, USD Million, 2017 - 2028)
    • Contract
    • In-house

• End-use Outlook (Revenue, USD Million, 2017 - 2028)
    • Biotechnology and pharmaceutical companies
    • Academic and government research institutes
    • Contract research organizations

• Application Outlook (Revenue, USD Million, 2017 - 2028)
    • Genetic Engineering
        • Cell line engineering
        • Animal genetic engineering
        • Plant genetic engineering
        • Others
    • Clinical Applications
        • Diagnostics
        • Therapy Development

• Regional Outlook (Revenue, USD Million, 2017 - 2028)
    • North America
        • U.S.
        • Canada
    • Europe
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
    • Asia Pacific
        • Japan
        • China
        • India
        • South Korea
    • Latin America
        • Brazil
        • Mexico
    • Middle East and Africa (MEA)
        • South Africa
        • Saudi Arabia